Our mission is to develop innovative treatments to improve the lives of individuals suffering from neuropsychiatric and neurologic disorders, in order to reduce the burden on patients and their caregivers.
Headquartered in NYC and founded in 2002, ITCI is focused on developing innovative medicines to improve the lives of patients suffering from CNS disorders.
Lumateperone is a novel, new molecular entity in development for the treatment of neuropsychiatric and neurodegenerative diseases.Read more
Check out our corporate presentation here.Read more
Find out the latest about Intra-Cellular here.Read more
The safety and efficacy of these investigational agents have not been established.